ATE414078T1 - Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten - Google Patents

Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten

Info

Publication number
ATE414078T1
ATE414078T1 AT06777681T AT06777681T ATE414078T1 AT E414078 T1 ATE414078 T1 AT E414078T1 AT 06777681 T AT06777681 T AT 06777681T AT 06777681 T AT06777681 T AT 06777681T AT E414078 T1 ATE414078 T1 AT E414078T1
Authority
AT
Austria
Prior art keywords
ylcarbonylpiperidine
indol
receptor antagonists
benzimidazole derivatives
benzimidazole
Prior art date
Application number
AT06777681T
Other languages
English (en)
Inventor
Caterina Bissantz
Christophe Grundschober
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE414078T1 publication Critical patent/ATE414078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06777681T 2005-07-21 2006-07-11 Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten ATE414078T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05106695 2005-07-21
EP05110506 2005-11-09

Publications (1)

Publication Number Publication Date
ATE414078T1 true ATE414078T1 (de) 2008-11-15

Family

ID=37192471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06777681T ATE414078T1 (de) 2005-07-21 2006-07-11 Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten

Country Status (21)

Country Link
US (2) US7803815B2 (de)
EP (1) EP1912976B1 (de)
JP (1) JP4839374B2 (de)
KR (1) KR100984893B1 (de)
CN (1) CN101268067A (de)
AR (1) AR056188A1 (de)
AT (1) ATE414078T1 (de)
AU (1) AU2006271804B2 (de)
BR (1) BRPI0613656A2 (de)
CA (1) CA2616063A1 (de)
DE (1) DE602006003666D1 (de)
DK (1) DK1912976T3 (de)
ES (1) ES2314941T3 (de)
IL (1) IL188722A (de)
MX (1) MX2008000886A (de)
NO (1) NO20080291L (de)
PL (1) PL1912976T3 (de)
PT (1) PT1912976E (de)
RU (1) RU2415139C2 (de)
TW (1) TWI324601B (de)
WO (1) WO2007009906A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102295636A (zh) * 2005-07-29 2011-12-28 弗·哈夫曼-拉罗切有限公司 吲哚-3-基-羰基-哌啶和哌嗪衍生物
KR101050558B1 (ko) 2006-12-08 2011-07-19 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서 작용하는 인돌
PE20081401A1 (es) 2006-12-28 2008-10-24 Hoffmann La Roche Derivados de indol como antagonistas de receptores vasopresina
CA2712701A1 (en) * 2008-01-31 2009-08-06 Henning Steinhagen Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
ES2464598T3 (es) 2011-07-22 2014-06-03 Université Joseph Fourier Nuevos derivados bis-indólicos, procedimiento para su preparación, y sus utilizaciones como fármaco
SG11202001498QA (en) * 2017-09-05 2020-03-30 Blackthorn Therapeutics Inc Vasopressin receptor antagonists and products and methods related thereto
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
WO2020216378A1 (zh) * 2019-04-26 2020-10-29 健艾仕生物医药有限公司 一种含杂环的化合物、其应用及含其的组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
DE4414113A1 (de) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-Indolylpiperidine
DE19725664A1 (de) * 1997-06-18 1998-12-24 Merck Patent Gmbh 3-Benzylpiperidine
AUPP150098A0 (en) * 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
EP1330451B1 (de) * 2000-10-27 2008-01-23 Ortho-McNeil Pharmaceutical, Inc. Substituierte benzimidazol-2-one als vasopressin receptor antagonisten und neuropeptide y modulatoren
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds

Also Published As

Publication number Publication date
ES2314941T3 (es) 2009-03-16
KR100984893B1 (ko) 2010-10-01
AR056188A1 (es) 2007-09-26
EP1912976B1 (de) 2008-11-12
AU2006271804B2 (en) 2011-03-31
MX2008000886A (es) 2008-03-18
BRPI0613656A2 (pt) 2011-01-25
WO2007009906A1 (en) 2007-01-25
TW200740792A (en) 2007-11-01
DK1912976T3 (da) 2009-01-26
TWI324601B (en) 2010-05-11
IL188722A (en) 2012-12-31
PT1912976E (pt) 2009-01-07
RU2008100780A (ru) 2009-08-27
PL1912976T3 (pl) 2009-04-30
US20070021463A1 (en) 2007-01-25
CA2616063A1 (en) 2007-01-25
EP1912976A1 (de) 2008-04-23
US7803815B2 (en) 2010-09-28
AU2006271804A1 (en) 2007-01-25
IL188722A0 (en) 2008-08-07
JP4839374B2 (ja) 2011-12-21
US20100256140A1 (en) 2010-10-07
CN101268067A (zh) 2008-09-17
DE602006003666D1 (de) 2008-12-24
JP2009501757A (ja) 2009-01-22
KR20080027950A (ko) 2008-03-28
RU2415139C2 (ru) 2011-03-27
NO20080291L (no) 2008-03-06

Similar Documents

Publication Publication Date Title
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
ATE413874T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
ATE526325T1 (de) Substituierte benzimidazole als kinaseinhibitoren
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
ATE523195T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
ATE537151T1 (de) Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
DE602007012300D1 (de) Chiniclidinderivate von (hetero)arylcycloheptancarbonsäuren als antagonisten am muskarinrezeptor
ATE513827T1 (de) Oxyindol-derivate als 5ht4-rezeptor-agonisten
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE555785T1 (de) Triazolderivate als smo-antagonisten
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1912976

Country of ref document: EP